BURBANK, Calif., April 05, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNGD), a development stage
company introducing disruptive technologies in the medical imaging industry, has engaged MZ Group, a leading capital markets
communications firm to manage a comprehensive strategic investor awareness and financial communications program across all key
markets.
MZ Group will work closely with Imaging3 management to develop and roll out a comprehensive capital markets strategy
designed to grow the Company's visibility in the investment community. This structured campaign will highlight
Imaging3's innovative technology, expected healthcare economics impact, recent operational progress and strong IP
position in the medical imaging arena.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™,
that produces 3D x-ray images effectively “live” in real time. The SmartScan technology has the potential to allow healthcare
professionals to perform diagnostic and therapeutic procedures more quickly and accurately, which is expected to result in higher
throughput for clinicians and provide more information for healthcare providers to make more informed decisions. Additionally,
Imaging3’s technology benefits patients with lower exposures to harmful radiation than comparable imaging technologies
such as CT scans.
The Dominion scanner is designed to provide reasonably convenient portability, easier installation and use-readiness, operation
on 110V, and deliverability at a small fraction of the total installed cost of current CT scanning systems. Imaging3
believes the Dominion SmartScan feature set will allow 2D and 3D scanning to penetrate and add value in many novel clinical
settings and in healthcare systems across varied global settings, where scanning is currently limited by cost or concerns over
radiation exposure.
MZ Group has a distinguished reputation as a premier resource for institutional investors, brokers, analysts, and private
investors. The firm has six offices across North America, a strong presence in Asia and Brazil, and maintains extensive
relationships with investors throughout Europe. Additionally, MZ Group was recently ranked the No. 1 Latin American and No. 7 world
business communication firm.
“Having worked with the MZ Group before, I have been impressed with the level of professionalism they demonstrate and the
commitment they have to achieving their clients’ objectives. Their team is very effective in crafting and executing
comprehensive investor awareness strategies, and we anticipate that they will increase market recognition for Imaging3’s
remarkable potential on a broad scale. We are very excited to partner with them,” said Imaging3 CEO John
Hollister.
VP of MZ Group North America, Mike Cole, will be leading the team at MZ Group and oversee all facets of corporate and financial
communications for Imaging3, including coordinating roadshows in key cities and building brand awareness with the
financial media and analyst communities.
Ted Haberfield, President of MZ Group North America, commented, "MZ Group looks forward to partnering with John Hollister and
the Imaging3 team on this venture. John’s experience in leading both disruptive technology-based microcaps as well as
high growth startups will be invaluable in attacking what is currently a market ripe for a new, leading-edge technology player. His
degree of familiarity with our unique approach to shareholder communication, as well as to our base of microcap investors will help
drive the efficacy of our program and we’re excited to get started."
About MZ Group
MZ, founded in 1999, combines capital markets intelligence, global investor targeting, IR technology, corporate governance,
media and corporate communication and IR consulting, providing comprehensive programs that successfully build and manage
shareholder value. With a team of highly experienced senior professionals and an integrated service portfolio, MZ ensures that
companies are provided with the right tools and strategies to interact effectively with the investment community and the media,
successfully conveying the investment message. MZ's market intelligence, advisory and tactical support activities for investor
relations and corporate communications programs are underpinned by a comprehensive IT infrastructure, allowing companies to rapidly
achieve global standards of best practices. For more information, please visit www.mzgroup.us.
About Imaging3, Inc.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™,
that produces 3D x-ray images, effectively in real time. The SmartScan technology has the potential to allow healthcare
professionals to perform diagnostic and therapeutic procedures more quickly and accurately, which may result in higher throughput
for the clinicians and fewer safety risks for patients. Imaging3’s technology exposes patients to less harmful
radiation than current equivalent imaging technologies such as CT scans. The company believes this will allow scans to be
used in many settings where scanning is currently limited by concerns about radiation exposure. The technology also notably allows
for reasonably convenient portability, easier installation and use-readiness, and a significantly reduced cost burden suitable for
novel settings and for healthcare systems across varied global settings. Imaging3 plans to submit a 510(k)
application to FDA during 2018 to gain marketing authorization for initial applications for the SmartScan technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the company’s technology.
Safe Harbor for Forward-Looking Statements
Imaging3 cautions you that any statement included in this press release that is not a description of historical facts
is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate,"
"may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those
contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based
largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in Imaging3’s
business, including, without limitation: the company may not ever obtain FDA clearance or approval for any of its devices; the
company may not be able to secure the funds necessary to support its product development plans; and the company may not ever
achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to
economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected
costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3
and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the
Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q.
Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.
Investor Relations:
Mike Cole
Vice President
MZ Group - MZ North America
+1(949) 259-4988
mike.cole@mzgroup.us
www.mzgroup.us
